Voriconazole, but not terbinafine, markedly reduces alfentanil clearance and prolongs its half-life

Clinical Pharmacology and Therapeutics

Volumn 80, Issue 5, 2006, Pages 502-508

  Saari, Teijo I ^a   Laine, Kari ^a   Leino, Kari ^a   Valtonen, Mika ^a   Neuvonen, Pertti J ^a   Olkkola, Klaus T ^a  

^a UNIVERSITY OF TURKU   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ALFENTANIL; CYTOCHROME P450 3A; CYTOCHROME P450 INHIBITOR; NALOXONE; TERBINAFINE; VORICONAZOLE;

ADULT; ANALGESIA; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; COLOR VISION; COLOR VISION DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG INHIBITION; DRUG METABOLISM; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; METHODOLOGY; NAUSEA; NORMAL HUMAN; PHOTOPHOBIA; PLASMA CLEARANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATION DEPRESSION; SEDATION; VOLUNTEER; VOMITING;

ADMINISTRATION, ORAL; ADULT; ALFENTANIL; ANALGESICS, OPIOID; ANTIFUNGAL AGENTS; AREA UNDER CURVE; COLOR VISION DEFECTS; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; ENZYME INHIBITORS; FEMALE; HALF-LIFE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; METABOLIC CLEARANCE RATE; NAPHTHALENES; PHOTOPHOBIA; PYRIMIDINES; SEX FACTORS; TRIAZOLES; VOMITING;

EID: 33751111707     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2006.07.008     Document Type: Article

References (39)

1. Meuldermans W., Van Peer A., Hendrickx J., Woestenborghs R., Lauwers W., Heykants J., et al. Alfentanil pharmacokinetics and metabolism in humans. Anesthesiology 69 (1988) 527-534
2. Kharasch E.D., Russell M., Mautz D., Thummel K.E., Kunze K.L., Bowdle A., et al. The role of cytochrome P450 3A4 in alfentanil clearance. Implications for interindividual variability in disposition and perioperative drug interactions. Anesthesiology 87 (1997) 36-50
3. Labroo R.B., Thummel K.E., Kunze K.L., Podoll T., Trager W.F., and Kharasch E.D. Catalytic role of cytochrome P4503A4 in multiple pathways of alfentanil metabolism. Drug Metab Dispos 23 (1995) 490-496
4. Klees T.M., Sheffels P., Dale O., and Kharasch E.D. Metabolism of alfentanil by cytochrome P4503A (CYP3A) enzymes. Drug Metab Dispos 33 (2005) 303-311
5. Tseng C.Y., Wang S.L., Lai M.D., Lai M.L., and Huang J.D. Formation of morphine from codeine in Chinese subjects of different CYP2D6 genotypes. Clin Pharmacol Ther 60 (1996) 177-182
6. Enggaard T.P., Poulsen L., Arendt-Nielsen L., Brosen K., Ossig J., and Sindrup S.H. The analgesic effect of tramadol after intravenous injection in healthy volunteers in relation to CYP2D6. Anesth Analg 102 (2006) 146-150
7. Heiskanen T., Olkkola K.T., and Kalso E. Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. Clin Pharmacol Ther 64 (1998) 603-611
8. Maitre P.O., Vozeh S., Heykants J., Thomson D.A., and Stanski D.R. Population pharmacokinetics of alfentanil: the average dose-plasma concentration relationship and interindividual variability in patients. Anesthesiology 66 (1987) 3-12
9. Boucher H.W., Groll A.H., Chiou C.C., and Walsh T.J. Newer systemic antifungal agents. Pharmacokinetics, safety and efficacy. Drugs 64 (2004) 1997-2020
10. Purkins L., Wood N., Greenhalgh K., Allen M.J., and Oliver S.D. Voriconazole, a novel wide spectrum triazole: oral pharmacokinetics and safety. Br J Clin Pharmacol 56 Suppl 1 (2003) 10-16
11. Hyland R., Jones B.C., and Smith D.A. Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole. Drug Metab Dispos 31 (2003) 540-547
12. Niwa T., Shiraga T., and Takagi A. Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes. Biol Pharm Bull 28 (2005) 1805-1808
13. Purkins L., Wood N., Kleinermans D., and Nichols D. Voriconazole potentiates warfarin-induced prothrombin time prolongation. Br J Clin Pharmacol 56 Suppl 1 (2003) 24-29
14. Romero A.J., Le Pogamp P., Nilsson L.-G., and Wood N. Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant patients. Clin Pharmacol Ther 71 (2002) 226-234
15. Saari T.I., Laine K., Leino K., Valtonen M., Neuvonen P.J., and Olkkola K.T. Effect of voriconazole on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Clin Pharmacol Ther 79 (2006) 362-370
16. Abdel-Rahman S.M., and Nahata M.C. Oral terbinafine: a new antifungal agent. Ann Pharmacother 31 (1997) 445-456
17. Vickers A.E., Sinclair J.R., Zollinger M., Heitz F., Glanzel U., Johanson L., et al. Multiple cytochrome P-450s involved in the metabolism of terbinafine suggest a limited potential for drug-drug interactions. Drug Metab Dispos 27 (1999) 1029-1038
18. Abdel-Rahman S.M., Gotschall R.R., Kauffman R.E., Leeder J.S., and Kearns G.L. Investigation of terbinafine as a CYP2D6 inhibitor in vivo. Clin Pharmacol Ther 65 (1999) 465-472
19. Varhe A., Olkkola K.T., and Neuvonen P.J. Fluconazole, but not terbinafine, enhances the effects of triazolam by inhibiting its metabolism. Br J Clin Pharmacol 41 (1996) 319-323
20. Ahonen J., Olkkola K.T., and Neuvonen P.J. Effect of itraconazole and terbinafine on the pharmacokinetics and pharmacodynamics of midazolam in healthy volunteers. Br J Clin Pharmacol 40 (1995) 270-272
21. Bartkowski R.R., Goldberg M.E., Larijani G.E., and Boerner T. Inhibition of alfentanil metabolism by erythromycin. Clin Pharmacol Ther 46 (1989) 99-102
22. Palkama V.J., Isohanni M.H., Neuvonen P.J., and Olkkola K.T. The effect of intravenous and oral fluconazole on the pharmacokinetics and pharmacodynamics of intravenous alfentanil. Anesth Analg 87 (1998) 190-194
23. Ahonen J., Olkkola K.T., Salmenpera M., Hynynen M., and Neuvonen P.J. Effect of diltiazem on midazolam and alfentanil disposition in patients undergoing coronary artery bypass grafting. Anesthesiology 85 (1996) 1246-1252
24. Kharasch E.D., Walker A., Hoffer C., and Sheffels P. Evaluation of first-pass cytochrome P4503A (CYP3A) and P-glycoprotein activities using alfentanil and fexofenadine in combination. J Clin Pharmacol 45 (2005) 79-88
25. Gage R., and Stopher D.A. A rapid HPLC assay for voriconazole in human plasma. J Pharm Biomed Anal 17 (1998) 1449-1453
26. Pennick G.J., Clark M., Sutton D.A., and Rinaldi M.G. Development and validation of HPLC assay for voriconazole. Antimicrob Agents Chemother 7 (2003) 2348-2350
27. Kovarik J.M., Kirkesseli S., Humbert H., Grass P., and Kutz K. Dose-proportional pharmacokinetics of terbinafine and its N-demethylated metabolite in healthy volunteers. Br J Dermatol 126 Suppl 39 (1992) 8-13
28. Krivoruk Y., Kirinons M.T., Wood A.J.J., and Wood M. Alfentanil disposition in vivo mediated by human CYP3A4 in humans. Anesthesiology 81 (1994) A380
29. Stanski D.R., and Hug Jr. C.C. Alfentanil-a kinetically predictable narcotic analgesic. Anesthesiology 57 (1982) 435-438
30. Abdel-Rahman S.M., Marcucci K., Boge T., Gotschall R.R., Kearns G.L., and Leeder J.S. Potent inhibition of cytochrome P-450 2D6-mediated dextromethorphan O-demethylation by terbinafine. Drug Metab Dispos 27 (1999) 770-775
31. Castberg I., Helle J., and Aamo T.O. Prolonged pharmacokinetic drug interaction between terbinafine and amitriptyline. Ther Drug Monit 27 (2005) 680-682
32. Madani S., Barilla D., Cramer J., Wang Y., and Paul C. Effect of terbinafine on the pharmacokinetics and pharmacodynamics of desipramine in healthy volunteers identified as cytochrome P450 2D6 (CYP2D6) extensive metabolizers. J Clin Pharmacol 42 (2002) 1211-1218
33. Handal K.A., Schauben J.L., and Salamone F.R. Naloxone. Ann Emerg Med 12 (1983) 438-445
34. Langevin S., Lessard M.R., Trepanier C.A., and Baribault J.P. Alfentanil causes less postoperative nausea and vomiting than equipotent doses of fentanyl or sufentanil in outpatients. Anesthesiology 91 (1999) 1666-1673
35. Gold B.S., Kitz D.S., Lecky J.H., and Neuhaus J.M. Unanticipated admission to the hospital following ambulatory surgery. JAMA 262 (1989) 3008-3010
36. Roberts G.W., Bekker T.B., Carlsen H.H., Moffatt C.H., Slatery P.J., and McClure A.F. Postoperative nausea and vomiting are strongly influenced by postoperative opioid use in a dose-related manner. Anesth Analg 101 (2005) 1343-1348
37. Klees T.M., Sheffels P., Thummel K.E., and Kharasch E.D. Pharmacogenetic determinants of human liver microsomal alfentanil metabolism and the role of cytochrome P450 3A5. Anesthesiology 102 (2005) 550-556
38. Cummins C.L., Wu C.Y., and Benet L.Z. Sex-related differences in the clearance of cytochrome P450 3A4 substrates may be caused by P-glycoprotein. Clin Pharmacol Ther 72 (2002) 474-489
39. Ikeda Y., Umemura K., Kondo K., Sekiguchi K., Miyoshi S., and Nakashima M. Pharmacokinetics of voriconazole and cytochrome p450 2C19 genetic status. Clin Pharmacol Ther 75 (2004) 586-588